Clinical Trial

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma

Study acronym: LEVERAGE
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The trial will investigate the combination of venetoclax, obinutuzumab and lenalidomide in patients with treatment-naïve follicular lymphoma. Patients will receive induction treatment for 0.5 years with venetoclax, obinutuzumab and lenalidomide followed by maintenance treatment for upto 2 years. Maintenance treatment will be determined by the response at the end of induction. Following completion of treatment patients will be followed up for 3 years after the last patient completes induction treatment.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-06-06; most recent amendment 2024-07-26.
Status change: Recruiting → Active, Not Recruiting 2024-07-26
Status change: Not Yet Recruiting → Recruiting 2019-09-17
Trial Details
NCT Number NCT03980171
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions Follicular Lymphoma
Enrollment 50 participants
Start Date 2019-08-19
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2024-07-29